ACT Genomics announces partnership with Quark Biosciences to develop tumor micro-environment chip (TME Chip) as a universal biomarker for cancer immunotherapy. The TME chip will help predict whether a cancer patient is suitable to receive immune checkpoint inhibitors, as well as facilitate researches on immunotherapy. Of the predicting factors for immunotherapy responses, Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI) can already be measured by ACT Genomics’ ACTOnco®+. By developing the TME chip, ACT Genomics hopes to shed light on another key predicting factor, tumor mirco-environment (TME), in order to address the issue of low response rate in immunotherapy.
Quark Biosciences is an optical-electronic engineering company aiming to enable precision medicine by delivering biomarker panels to resolve unmet clinical needs. Quark Biosciences: https://www.quarkbiosciences.com/